Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium : potential diagnostic application in postmenopausal patients

• Published in: Cancer research (Chicago, Ill.) Ill.), 1991-06, Vol.51 (11), p.3001-3005
• Main Authors: BARTOLAZZI, A, MOTTOLESE, M, VOACTURO, A, BIGOTTI, A, VOCATURO, G, ATLANTE, G, PRAT, M, NATALI, P. G
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal; Antigens, Neoplasm - analysis; Antigens, Neoplasm - immunology; Antigens, Tumor-Associated, Carbohydrate - analysis; Antigens, Tumor-Associated, Carbohydrate - immunology; Biological and medical sciences; Endometrium - immunology; Female; Female genital diseases; Glycoproteins - analysis; Glycoproteins - immunology; Gynecology. Andrology. Obstetrics; Humans; Hyperplasia - immunology; Medical sciences; Precancerous Conditions - immunology; Tumors; Uterine Neoplasms - immunology
• ISSN: 0008-5472; 1538-7445

Mass cytoscreening for the early diagnosis of endometrial carcinoma has thus far been hampered by the low diagnostic accuracy of current cytopathology. In this study we have analyzed the reactivity of the two monoclonal antibodies, AR-3 and B72.3, recognizing two distinct glycosylated high molecular weight carcinoma associated antigens on histological specimens from normal, hyperplastic, and transformed endometrium with the aim of establishing their diagnostic potential. Because women with a high risk of endometrial cancer are frequently postmenopausal, where normal endometrium is characterized by atrophy and cystic glandular hyperplasia, the following findings were of interest. Both antibodies reacted with variable and apical staining patterns with a minority of specimens of normal cycling endometrium from premenopausal women. However, they were constantly negative when tested on normal atrophic postmenopausal endometrium, and only monoclonal antibody AR-3 occasionally stained glandular cystic hyperplasia. By contrast, lesions with atypical hyperplasia, which represent a preneoplastic condition, were stained by both antibodies in 89 or 67% of the cases depending on the monoclonal antibody used (100% if used in combination). Furthermore, 98% of the endometrial carcinomas tested were found to react with the combination of two monoclonal antibodies. If these findings are confirmed in a multicentric study, the use of the two reagents could be a valuable adjunct in the cytodiagnosis of endometrial cancer, especially in providing a guideline to selecting patients for endometrial curettage and additional diagnostic procedures.